Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendment to the Terms of Convertible Loan Stock

8 Dec 2017 07:00

RNS Number : 7627Y
Sopheon PLC
08 December 2017
 

Embargoed Release: 07:00hrs Friday 8 December

 

 

SOPHEON PLC

 

AMENDMENT TO THE TERMS OF CONVERTIBLE LOAN STOCK

 

Sopheon plc ("Sopheon", the "Company" or the "Group") announces that it has reached agreement with the holders of its remaining £1.94m of convertible unsecured loan stock (the "Loan Stock") to convert it into equity by the end of 2017. 

 

As previously announced, in 2009 and 2011, the Company issued a total of £2m of Loan Stock to a group of investors including members of the Board and senior management team. The Loan Stock, which carries an interest coupon at a rate of 8 percent per annum, is currently due to mature on 31 January 2019, and has a conversion price of 76.5p per ordinary share of 20p each in the Company ("Ordinary Shares"). Board members with an interest in the Loan Stock are Barry Mence (£640,000), Andrew Michuda (£45,000), Arif Karimjee (£27,000) and Stuart Silcock (£200,000). Rivomore Limited, a current substantial shareholder in the Company, has an interest in the Loan Stock of £640,000.

 

Proposals have yesterday been put to the holders of the Loan Stock that would reconstitute the instrument such that it would automatically convert to equity on 22 December 2017, at the conversion price stated above, resulting in the issue of 2,535,947 new Ordinary Shares. This change will improve the profile of the Group's year end balance sheet and simplify the capital structure, as well as eliminating the interest charge going forward. In conjunction with this proposed amendment, a one-off payment of 8 percent of the face value of the Loan Stock will be made to holders of the Loan Stock in cash amounting to approximately £155,000, in recognition of the loss of their interest and repayment rights as a result of the early conversion. Irrevocable undertakings have been received from holders representing almost £1.7m of the Loan Stock, being over 85 per cent of the Loan Stock in issue, to vote in favour of a resolution to authorise the amendment of the Loan Stock instrument as described above at a forthcoming meeting of the Loan Stock holders on 22 December 2017 (the "Meeting").

 

The modification of the terms of the Loan Stock constitutes a related party transaction for the purposes of AIM Rule 13. In accordance with the AIM Rules for Companies, Daniel Metzger, as the director independent with respect to this transaction, having consulted with the Company's Nominated Adviser, finnCap Limited, considers that the amendment to the terms of the Loan Stock are fair and reasonable insofar as the Company's shareholders are concerned.

 

Following formal approval by Loan Stock holders at the Meeting, application will be made for the 2,535,947 new Ordinary Shares to be admitted to trading on AIM, and dealings expected to commence on 27 December 2017. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. A further announcement will be made following the Meeting.

 

 

Sopheon's Chairman, Barry Mence said: "I am delighted and grateful that our convertible loan stock holders have continued to show such solid support for the Company, as they have through the last several years of our development as a business. With these changes we will enter 2018 with a clearer capital structure and an enhanced balance sheet."

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener / Camille Gochez (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 250 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEADAXELDXFAF
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.